Researchers evaluated the association between metformin and survival in women with type 2 diabetes and 3 hormone-related cancers — breast, ovarian, and endometrial cancer.
Lenvatinib-pembrolizumab produced better outcomes than did chemotherapy, both overall and among patients with mismatch repair-proficient disease.
A meta-analysis suggests that coffee may provide a protective effect against endometrial cancer.
Changes in weight and BMI were associated with disease-free and overall survival.
The duration of response was more than 3 years in 68% of patients.
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.
More research is needed before radiomics can be used in clinical practice, according to researchers.
Factors other than access may affect differences in survival, according to researchers.
The disparity is due to the greater prevalence of fibroids and nonendometrioid histologic type in Black women, according to researchers.
